Global Bioenergies (FR0011052257, ALGBE) today announced its successful IPO on the NYSE Alternext in Paris to raise funds of around 6.6 million euros, after full exercise of the extension clause and the over-allotment option.The Sony VGP-BPS13/Q Battery price applicable to the Global Placement and Open Offer Price has been set at € 19.85 per share, the upper limit of the indicative range for IPO originally proposed between € 16.25 and € 19.85 per share.
The number of new shares issued by the Company in connection with the operation amounted to 333,675, representing 21.1% of the capital after issue of new shares. Masseran Management, a shareholder of Global Bioenergies, 133 000 new shares subscribed.
Demand in the amounts of OCT to € 6.9 million representing an oversubscription of 13.8 times. A service rate of 43.9% in A1 order of the OPO was announced by NYSE-Euronext. No order was served on A2 due to the high demand.
The total number of shares applied for under the offering was 388,360 shares, representing an oversubscription of 1.7 times.
Given the huge demand in the OPO, it was decided to focus on retail investors 23% of the shares offered after the exercise of the extension clause, against 10% originally planned. The allocation of shares subscribed 333,675 as follows:
Offering: 266,940 shares allocated to institutional investors;
Open Price Offer: 66,735 shares allocated to the public in France.
Crystal Sugar Group Union participated in the operation of € 1 million under the Global Offering
Cristal Union, a major player in the sugar hp pavilion dv4 battery industry has contributed to the operation, under the Global Offering, up to € 1 million. Global Bioenergy is delighted to welcome such a player of industrial capital, operating in related and complementary.
Based on the price of 19.85 euros per share, the market capitalization of the Company amounted to approximately 31.4 million after the completion of the transaction (after full exercise of the clause and the expansion option allotment).
Fundraising conducted by Global Bioenergies enable it to implement its development plan and provide the necessary financial resources, including:
To finance the first phase of industrialization of isobutene
To replicate the success to other molecules of the same family (ethylene, propylene, butene, butadiene, isoprene), corresponding to an even larger market.
After the offering, the Company's capital consists of 1,580,175 shares. Its capital is allocated as follows:
Management Masseran 1,639,500 40.5%
Philippe Marlière 358 900 22.7%
Marc Delcourt 358,860 22.7%
Public 222,915 14.1%
Total 1,580,175 100.0%
Note (1): Masseran Management, a subsidiary of BPCE dedicated to the activities of venture capital, was served up to 90%.
The settlement shares will be June 14, 2011. The shares will trade from Wednesday, June 15, 2011 in continuous trading.
The shares will begin on the NYSE Alternext Paris under ISIN code FR0011052257 and mnemonic ALGB.
Marc Delcourt, co-founder and CEO of Global Bioenergy, said: "We are very pleased with the enthusiasm of the Global Bioenergy we met, we assigned individual shareholders a bigger stake than originally Sony VGP-BPS13B/Q Battery planned, because we thought it was important to meet this expectation. the public directly and actively in our innovation efforts. I thank them and all institutional investors for their confidence in us. I think the last entry in the capital structure of the Union of Crystal Group, in recognition of the validity of our approach. Global Bioenergy now has the resources necessary for their development. "
In the prospectus:
Copies of the prospectus filed 25th May 2011 under number 11-180 by the AMF, are available free on request from the Global Bioenergy, 5, rue Henri Desbruères 91000 Evry, and in the north of credit, 50 rue d' Anjou 75008 Paris. This Sony VGP-BPS9/b Battery document is also available online on the AMF website (www.amf-france.org) and Global Bio-Energy (www.global-bioenergies.com).
• Risk factors
Global Bioenergies draws public attention to the risks associated with activities in Chapter 4 of the first part of the prospectus and the risks associated with the operation of an IPO in Chapter 2 of the second part of the prospectus registered 25th May 2011 associated with the number 11 -180 described by the AMF
• additional tax
To benefit HP Pavilion dv7 battery individual subscribers, if any, reduction to meet the tax and solidarity tax on wealth, under the new shares of the Company as provided in each case, I committed the 2nd section 199 of the A-0 terdecies Tax Code (relating to reducing IR) and defined in letters a to g of V § 1885-0 of the Code (relating to the reduction of ISF), within the laws and regulations .
Requests for individual state will be processed on a first come, according to the rule "first come, first served." Global Bioenergy reserves the right to close the transaction in advance, if the limit is reached 2, 5 million, given the requests already in the last 12 months.
About Global Bioenergy
Founded in 2008 by Marc and Philippe Delcourt Marliere at Genopole (Evry), Global Bioenergy is one of the few companies in the world and the only one in Europe to develop a method for converting renewable Sony VAIO VGN-FZ Battery resources into hydrocarbons. The company was successful and ahead of schedule, the first stages of its development process for the conversion of plant material isobutene: proof of concept, the construction of strains in the laboratory-scale prototype. Isobutene is one of the building blocks of the largest petrochemicals, which can be converted into fuels, plastics, organic glass and rubber. Global Bioenergies continue to improve the performance of his trial and is preparing to test the pilot plant. In parallel, the Sony VGP-BPL13 Battery company intends to replicate this success with other molecules of the family of gaseous olefins (propylene, ethylene, butylene'...), linear molecules of petrochemical plants, only now recovered from oil.